Journal: Journal of Experimental & Clinical Cancer Research : CR
Article Title: DNA damaging agents boost the transcription of endothelin A receptor in high-grade serous ovarian cancer
doi: 10.1186/s13046-025-03607-0
Figure Lengend Snippet: Olaparib- or cisplatin-induced activation of the DNA Damage Response cascade mediates ET A R upregulation. A IB of pATM, ATM, pATR, ATR and ET A R protein expression levels of PD HG-SOC cells treated or not with 10 µM olaparib for the indicated times. Tubulin was used as loading control. B IB of pATM, ATM, pATR, ATR, pCHK1, CHK1 and ET A R protein expression levels of PD HG-SOC cells treated or not with 10 µM olaparib for 48 h. C IB of ET A R, pCHK2, CHK2 and γH2A.X protein expression levels of PD HG-SOC cells treated with ATM inhibitor (ATMi, 5 µM) and/or olaparib (10 µM). Quantification of ET A R and γH2A.X protein expression normalized to tubulin, and pCHK2 normalized to total CHK2 and tubulin. All data are presented as mean ± SD expressed as fold induction ( n = 3, * p < 0,02 vs. non-treated cells; ** p < 0,008 vs. olaparib-treated cells). D IB of ET A R, pCHK1, CHK1 and γH2A.X expression levels of PD HG-SOC cells treated with ATR inhibitor (ATRi, 2,5 µM) and/or olaparib (10 µM). Quantification of ET A R, γH2A.X protein expression normalized to tubulin, and pCHK1 normalized to total CHK1 and tubulin ( n = 3, * p < 0,02 vs. non-treated cells; ** p < 0,02 vs. olaparib-treated cells). E IB of pATM, ATM, pATR, ATR, pCHK1, CHK1 and ET A R protein expression levels of PD HG-SOC cells treated or not with 10 µM cisplatin for 48 h. F IB of ET A R, pCHK2, CHK2 and γH2A.X protein expression levels of PD HG-SOC cells treated with ATMi (5 µM) and/or cisplatin (10 µM). Quantification of ET A R, γH2A.X and pCHK2 protein expression performed as in C ( n = 3, * p < 0,04 vs. non-treated cells; ** p < 0,002 vs. cisplatin-treated cells). G IB of ET A R, pCHK1, CHK1 and γH2A.X protein expression levels of PD HG-SOC cells treated with ATRi (2,5 µM) and/or cisplatin (10 µM). Quantification of ET A R, γH2A.X and pCHK1 protein expression performed as in D ( n = 3, * p < 0,05 vs. non-treated cells; ** p < 0,04 vs. cisplatin-treated cells)
Article Snippet: ATR kinase inhibitor (AZD6738, Ceralasertib, cat. no. HY-19323, MedChemExpress, USA) was added for 48 h at 2,5 μM.
Techniques: Activation Assay, Expressing, Control